Nasdaq

Algernon NeuroScience Announces 40 Patient Phase 2 Psychedelic Drug DMT Stroke Study

VANCOUVER, British Columbia, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT: AGW0 ...
Benzinga.com

2PHRRF : PharmaTher's DMT Patch Shows Positive Outcomes, Investment Toward...

PharmaTher Holdings PHRRF and the Terasaki Institute for Biomedical Innovation evaluated the former’s novel microneedle patch for the delivery of DMT, and research yielded positive outcomes. The study ...
Seeking Alpha

Algernon NeuroScience and the Centre for Human Drug Research to Present DMT Phase 1 Stroke Clinical Data at the Interdisciplinary Conference on Psychedelic Research June 6 ...

VANCOUVER, British Columbia, April 24, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian clinical stage ...
Nasdaq

Small Pharma Completes Enrollment in Phase IIa DMT-Assisted Psychotherapy Clinical Trial in Patients With Major Depressive Disorder

LONDON, Sept. 19, 2022 (GLOBE NEWSWIRE) -- Small Pharma Inc. (TSXV: DMT) (OTCQB: DMTTF) (the “Company” or “Small Pharma”), a biotechnology company focused on short-acting psychedelic-assisted ...
Healio

Patents issued for ‘world’s first’ psilocybin salts, polymorphs

Please provide your email address to receive an email when new articles are posted on . Terran Biosciences was issued patents for four patents in psychedelic treatments. Patents were issued for the ...